[go: up one dir, main page]

AU2002218751A1 - Stable radiopharmaceutical compositions - Google Patents

Stable radiopharmaceutical compositions

Info

Publication number
AU2002218751A1
AU2002218751A1 AU2002218751A AU1875102A AU2002218751A1 AU 2002218751 A1 AU2002218751 A1 AU 2002218751A1 AU 2002218751 A AU2002218751 A AU 2002218751A AU 1875102 A AU1875102 A AU 1875102A AU 2002218751 A1 AU2002218751 A1 AU 2002218751A1
Authority
AU
Australia
Prior art keywords
radiopharmaceutical compositions
stable radiopharmaceutical
stable
compositions
radiopharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002218751A
Inventor
John A Barrett
Alan P. Carpenter Jr.
Shuang Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of AU2002218751A1 publication Critical patent/AU2002218751A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002218751A 2000-07-06 2001-07-05 Stable radiopharmaceutical compositions Abandoned AU2002218751A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21639600P 2000-07-06 2000-07-06
US60/216,396 2000-07-06
PCT/US2001/021261 WO2002004030A2 (en) 2000-07-06 2001-07-05 Stable radiopharmaceutical compositions

Publications (1)

Publication Number Publication Date
AU2002218751A1 true AU2002218751A1 (en) 2002-01-21

Family

ID=22806902

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002218751A Abandoned AU2002218751A1 (en) 2000-07-06 2001-07-05 Stable radiopharmaceutical compositions

Country Status (5)

Country Link
US (1) US20020122768A1 (en)
EP (1) EP1311301A2 (en)
AU (1) AU2002218751A1 (en)
CA (1) CA2413538A1 (en)
WO (1) WO2002004030A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
BR9917079A (en) 1998-12-18 2001-10-30 Du Pont Pharm Co Devitronectin receptor antagonist compounds, kit, diagnostic or therapeutic metallopharmaceutical composition, ultrasound contrast agent composition, therapeutic radiopharmaceutical composition, diagnostic pharmaceutical composition, treatment method for rheumatoid arthritis, cancer and darthenosis in a patient, angiogenesis formation method therapy, cancer, new blood vessels, arteriosclerosis, darthenosis, ischemia and myocardial reperfusion injury in a patient
EP1307226B1 (en) * 2000-06-21 2008-11-19 Lantheus Medical Imaging, Inc. Vitronectin receptor antagonist pharmaceuticals
CA2413328A1 (en) * 2000-06-21 2001-12-27 Milind Rajopadhye Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
EP1311292A2 (en) * 2000-06-21 2003-05-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
BR0207315A (en) * 2001-02-26 2004-02-10 Bristol Myers Squibb Pharma Co Ascorbic acid analogues for metalloradiopharmaceuticals
US20030198593A1 (en) * 2002-04-15 2003-10-23 Frank R. Keith Radioprotectants for radiopharmaceutical formulations
US7018614B2 (en) * 2002-11-05 2006-03-28 Eastern Isotopes, Inc. Stabilization of radiopharmaceuticals labeled with 18-F
JP2006505610A (en) * 2002-11-05 2006-02-16 イヨン ベアム アプリカスィヨン エッス．アー． Stabilization of 18-F labeled radiopharmaceuticals
EP1622647B1 (en) * 2003-05-12 2009-11-25 Lantheus Medical Imaging, Inc. Vitronectin receptor antagonist compounds and their use in the preparation of radiopharmaceuticals
KR101106533B1 (en) * 2003-07-24 2012-01-20 브라코 이미징 에스.피.에이. Stable radiopharmaceutical compositions and methods for preparation
WO2005032599A1 (en) * 2003-09-30 2005-04-14 Semafore Pharmaceuticals Inc. Chelate based scaffolds in tumor targeting
GB0514087D0 (en) * 2005-07-11 2005-08-17 Ge Healthcare Ltd Stabilised radiopharmaceutical compositions
DK1968651T3 (en) 2005-12-22 2013-06-17 Univ Duke Stabilized compositions and methods for radioactive labeling of drugs with alpha-particle emitters
WO2007115132A2 (en) * 2006-03-29 2007-10-11 Guilford F Timothy Radiopharmaceutical in self-forming liposomal formulation capable of multipath administration including other ingredients
CN101621997B (en) * 2007-01-26 2013-05-08 株式会社宝丽制药 Pharmaceutical composition
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
DK3158991T3 (en) 2010-01-28 2021-06-14 Eagle Pharmaceuticals Inc BENDAMUSTIN FORMULATIONS
CN101865894B (en) * 2010-06-28 2012-11-21 江苏奥赛康药业股份有限公司 Method for detecting impurities in freeze-dried powder injection of nedaplatin
EP2726494B1 (en) 2011-06-28 2017-01-04 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
WO2013093099A1 (en) * 2011-12-22 2013-06-27 Piramal Imaging Sa Stabilization of peptidic radiopharmaceuticals using uric acid or derivatives thereof
FR2995536B1 (en) * 2012-09-17 2014-09-26 Lemer Prot Anti X Par Abreviation Soc Lemer Pax MEDICAL UNIT FOR THE INJECTION OF RUBIDIUM 82 TO A PATIENT
WO2014183071A2 (en) 2013-05-10 2014-11-13 Whitehead Institute For Biomedical Research In vitro production of red blood cells with sortaggable proteins
JP6603209B2 (en) 2013-05-10 2019-11-06 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ Protein modification of living cells using sortase
US10556024B2 (en) 2013-11-13 2020-02-11 Whitehead Institute For Biomedical Research 18F labeling of proteins using sortases
EP4218833A1 (en) * 2015-10-01 2023-08-02 Whitehead Institute for Biomedical Research Labeling of antibodies
EP3534969A4 (en) * 2016-11-04 2020-07-01 Clarity Pharmaceuticals Ltd FORMULAS FOR RADIATION THERAPY AND DIAGNOSTIC IMAGING
CN108241032B (en) * 2016-12-23 2020-10-16 江苏奥赛康药业有限公司 Method for analyzing nedaplatin
US11351276B2 (en) * 2018-06-22 2022-06-07 Jubilant Draximage Inc. Radiopharmaceutical compositions of radioactive halogenated benzylguanidine
CN115175910A (en) * 2019-11-08 2022-10-11 昆士兰大学 Radiolabelled targeting ligands
WO2022085571A1 (en) * 2020-10-22 2022-04-28 日本メジフィジックス株式会社 Method for producing radioactive zirconium complex
CN112546247A (en) * 2020-12-03 2021-03-26 西南医科大学附属医院 Application of polyhydroxy phenol compound, radiopharmaceutical composition and preparation method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0313712B1 (en) * 1987-10-30 1992-07-29 SORIN BIOMEDICA S.p.A. Stable radiodiagnostic compositons and their preparation
ES2150916T3 (en) * 1991-08-29 2000-12-16 Mallinckrodt Medical Inc USE OF GENISTIC ACID OR GENTISILIC ALCOHOL TO STABILIZE RADIO-MARKED PEPTIDES AND PROTEINS.
WO1997028181A2 (en) * 1996-02-02 1997-08-07 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
EE200000574A (en) * 1998-03-31 2002-10-15 Dupont Pharmaceuticals Company Pharmaceutical compounds for displaying angiogenic disorders
GB0015242D0 (en) * 2000-06-22 2000-08-16 Nycomed Amersham Plc Stabiliser for radiopharmaceuticals

Also Published As

Publication number Publication date
CA2413538A1 (en) 2002-01-17
WO2002004030A3 (en) 2003-02-27
WO2002004030A2 (en) 2002-01-17
EP1311301A2 (en) 2003-05-21
US20020122768A1 (en) 2002-09-05

Similar Documents

Publication Publication Date Title
AU2002218751A1 (en) Stable radiopharmaceutical compositions
AU2001292783A1 (en) Antireflective composition
AU2001233691A1 (en) Antiperspirant compositions
AU2001282877A1 (en) Cosmetic compositions
AU2001250420A1 (en) Pharmaceutical compositions
AU2001274307A1 (en) Pharmaceutical compositions
AU2001265919A1 (en) Cosmetic compositions
AU2001282617A1 (en) Compositions for external preparations
AUPQ875700A0 (en) Combination compositions
AU2001285790A1 (en) Antiperspirant compositions
AU2001241098A1 (en) Composition
GB0019651D0 (en) Compositions
AU2001273919A1 (en) Pharmaceutical compositions
AU2001215831A1 (en) Fragrance compositions
AU2681500A (en) Rapidly-soluble compositions
AU2002210433A1 (en) Dental compositions
AU2001270235A1 (en) Oral compositions
AU5085300A (en) Compositions
AU2001275201A1 (en) Acne-treating composition
AU2001256202A1 (en) Cosmetic compositions
AU2001235764A1 (en) Compositions
AU2001287852A1 (en) Composition
AU2000274826A1 (en) Cosmetic compositions
AU2001290669A1 (en) Oral compositions
AU2002228899A1 (en) Fragrance enhancing compositions with non-polycyclics